Novartis has claimed accelerated approval from the FDA for a second indication for Fabhalta – IgA nephropathy (IgAN) – as it charts a course to blockbuster sales for the drug. The US regulator ...
Arrowhead Pharmaceuticals’ phase 1/2a study has found the company’s investigational RNA interference (RNAi) candidate was generally well tolerated among 14 patients with kidney disease.
The new Oxford classification of IgA nephropathy has been developed as a pathological classification system to reliably predict the risk of disease progression. Future studies need to demonstrate ...
Present at the contract signing were GMA Network President and CEO Gilberto R. Duavit, Jr., Executive Vice President and Chief Financial Officer Felipe S. Yalong, GMA Public Affairs First Vice ...
Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...
Hosted on MSN3mon
Arnold Clavio gives moving speech as he renews contract with GMA Network: ‘Renewed human being po ako’Arnold Clavio remains a Kapuso. The GMA Integrated News and Public Affairs broadcast journalist renewed his contract on Tuesday at the “Unang Hirit” studio at the GMA Network Center in Quezon ...
Calliditas Therapeutics has broken new ground throughout its history. Having been the first company to deliver positive phase 3 data in the rare disease immunoglobulin A nephropathy (IgAN ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback